AVRO Overview

AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Wall Street analysts forecast AVRO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVRO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

AVROBIO Inc revenue for the last quarter amounts to -19.64M USD, decreased -6.89

AVROBIO Inc. EPS for the last quarter amounts to -19757000.00 USD, decreased -2.30

AVROBIO Inc (AVRO) has 13 emplpoyees as of May 12 2026.

Today AVRO has the market capitalization of 62.85M USD.